Paul L. Mitchell
Expertise in
22
conditions

Paul L. Mitchell

Hawkesbury Rd, 
Sydney, NSW, AU 
Expertise in
22
conditions
Hawkesbury Rd, 
Sydney, NSW, AU 

Overview

Paul Mitchell practices practicing medicine in Sydney, Australia.

Mr. Mitchell is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Cataract Removal, and Trabeculectomy.

He is actively involved in clinical research, co-authoring 1037 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Hawkesbury Rd, Sydney, NSW 2145, Australia
Other Locations
145 Studley Road, Heidelberg, VIC 3084, Australia
Studley Rd, Heidelberg, VIC, Australia
176 Hawkesbury Road, Westmead, NSW 2145, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

1035 Total Publications

Light- and X-ray-Activated Liposomes for Controlled Gene Editing and Drug Delivery.
Light- and X-ray-Activated Liposomes for Controlled Gene Editing and Drug Delivery.
Journal: Journal of visualized experiments : JoVE
Published: August 18, 2026

Frequently Asked Questions about Paul L. Mitchell

Is Paul L. Mitchell a top-rated expert for Age-Related Macular Degeneration (ARMD)?

MediFind is an objective health platform that identifies experts based on real-world data. Paul L. Mitchell is classified as an Distinguished expert for Age-Related Macular Degeneration (ARMD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paul L. Mitchell participate in research or clinical trials?

Yes. Paul L. Mitchell has published 1035 articles and abstracts on conditions like Age-Related Macular Degeneration (ARMD). You can view a list of Paul L. Mitchell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mitchell's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile